Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
Anteris announced it will present first 30-day clinical and hemodynamic outcomes for the medium-size DurAVR THV at TCT 2026 in San Diego, Oct 31-Nov 3. Azeem Latib will present the EMBARK study data on November 1, and Santiago Garcia will present a technology session on the biomimetic valve on November 3. The release contains no clinical results; it is a scheduling notice ahead of the data readout.
Key figures
- Drug Name
- DurAVR Transcatheter Heart Valve (THV)
- Phase Of Trial
- EMBARK study (ongoing) plus Early Feasibility Study
- Outcomes window
- 30-day clinical and hemodynamic outcomes
- Patients treated since 2021
- 130
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.